Translational Research
Volume 156, Issue 3 , Pages 188-205, September 2010

Stem cells and cell therapy approaches in lung biology and diseases

  • Viranuj Sueblinvong

      Affiliations

    • Division of Pulmonary, Critical Care and Allergy, Department of Medicine, Emory University, Atlanta, Ga
  • ,
  • Daniel J. Weiss

      Affiliations

    • Division of Pulmonary and Critical Care Medicine, University of Vermont College of Medicine, Burlington, Vt
    • Corresponding Author InformationReprint requests: Daniel J. Weiss, MD, Division of Pulmonary and Critical Care Medicine, University of Vermont College of Medicine, 149 Beaumont Avenue, HSRF 226, Burlington, VT 05405

Received 1 April 2010; received in revised form 14 June 2010; accepted 16 June 2010. published online 08 July 2010.

Cell-based therapies with embryonic or adult stem cells, including induced pluripotent stem cells, have emerged as potential novel approaches for several devastating and otherwise incurable lung diseases, including emphysema, pulmonary fibrosis, pulmonary hypertension, and the acute respiratory distress syndrome. Although initial studies suggested engraftment of exogenously administered stem cells in lung, this is now generally felt to be a rare occurrence of uncertain physiologic significance. However, more recent studies have demonstrated paracrine effects of administered cells, including stimulation of angiogenesis and modulation of local inflammatory and immune responses in mouse lung disease models. Based on these studies and on safety and initial efficacy data from trials of adult stem cells in other diseases, groundbreaking clinical trials of cell-based therapy have been initiated for pulmonary hypertension and for chronic obstructive pulmonary disease. In parallel, the identity and role of endogenous lung progenitor cells in development and in repair from injury and potential contribution as lung cancer stem cells continue to be elucidated. Most recently, novel bioengineering approaches have been applied to develop functional lung tissue ex vivo. Advances in each of these areas will be described in this review with particular reference to animal models.

Abbreviations: AEC, alveolar epithelial cell, ALI, acute lung injury, ARDS, acute respiratory distress syndrome, BASC, bronchioalveolar stem cell, CCSP, Clara cell secretory protein, CF, cystic fibrosis, CFTR, cystic fibrosis transmembrane conductance regulator, CLP, cecal ligation and puncture, COPD, chronic obstructive pulmonary disease, eNOS, endothelial nitric oxide synthetase, EPC, endothelial progenitor cell, ESC, embryonic stem cell, FEV1, forced expiratory volume in 1 second, FVC, forced vital capacity, GFP, green fluorescent protein, HSC, hematopoietic stem cell, IPF, idiopathic pulmonary fibrosis, KGF, keratinocyte growth factor, LPS, lipopolysaccharide, MCT, monocrotaline, MHC, major histocompatibility complex, MSC, mesenchymal stromal (stem) cell, PH, pulmonary hypertension, pro-SPC, pro-surfactant protein C, Sca-1, stem cell antigen-1

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by NHLBI HL087274 and HL081289 research grants from the Cystic Fibrosis Foundation and the American Lung Association and NCRR COBRE P20 RR-155557.

PII: S1931-5244(10)00122-2

doi:10.1016/j.trsl.2010.06.007

Translational Research
Volume 156, Issue 3 , Pages 188-205, September 2010